Gracell Biotechnologies : Corporate Presentation - January 2023

UNVEILING NEXT GEN CAR-T CELL THERAPIES

CORPORATE PRESENTATION JANUARY 2023

NASDAQ: GRCL

GRACELLBIO.COM

DISCLAIMER

This presentation has been prepared by Gracell Biotechnologies Inc. (the "Company") solely for information purpose and has not been independently verified. By viewing or accessing the information contained in this presentation, the recipient hereby acknowledges and agrees that no representations, warranties or undertakings, express or implied, are made by the Company or any of its directors, shareholders, employees, agents, affiliates, advisors or representatives as to, and no reliance should be placed upon, the accuracy, fairness, completeness or correctness of the information or opinions presented or contained in this presentation. None of the Company or any of its directors, shareholders, employees, agents, affiliates, advisors or representatives accept any responsibility whatsoever (in negligence or otherwise) for any loss howsoever arising from any information presented or contained in this presentation or otherwise arising in connection with the presentation. The information presented or contained in this presentation speaks as of the date of this presentation and is subject to change without notice.

Certain statements in this presentation, and other statements that the Company may make, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), Section 21E of the Securities Exchange Act of 1934, as amended., or the Private Securities Litigation Reform Act of 1995. These statements reflect the Company's intent, beliefs or current expectations about the future. These statements can be recognized by the use of words such as "expects," "plans," "will," "estimates," "projects," "intends," "anticipates," "believes," "confident" or words of similar meaning. These forward-looking statements are not guarantees of future performance and are based on a number of assumptions about the Company's operations and other factors, many of which are beyond the Company's control, and accordingly, actual results may differ materially from these forward-looking statements. The Company or any of its affiliates, advisers or

representatives has no obligation and does not undertake to revise forward-looking statements to reflect future events or circumstances.

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No securities of the Company may be sold in the United States without registration with the United States Securities and Exchange Commission (the "SEC") or an exemption from such registration pursuant to the Securities Act and the rules and regulations thereunder. No part of this presentation shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. Specifically, these materials do not constitute a "prospectus" within the meaning of the Securities Act. This presentation does not contain all relevant information relating to the Company or its securities, particularly with respect to the risks and special considerations involved with an investment in the securities of the Company and is qualified in its entirety by reference to those risks more fully discussed in the section titled "Risk Factors" in the Company's most recent annual report on Form 20-F, as well as discussions of potential risks, uncertainties, and other important factors in the Company's subsequent filings with the SEC.

2

REVOLUTIONIZING CAR-Tcell therapy.

Developing transformational solutions to broaden the use of

breakthrough cell therapies across

hematological and solid tumors.

3

At a Glance

Global, Clinical-Stage Biopharma Company

Clinically-validated

Technology Platforms

Next-day manufacturing autologous CAR-T with enhanced cell fitness

Off-the-shelf allogeneic CAR-T with optimized persistence

Rich, highly differentiated

Clinical Pipeline

6

Candidates currently in the clinic

100+

Patients dosed since 2017, leveraging investigator- initiated studies to accelerate innovation cycle

FASTCAR-T GC012F

Lead Asset

3

Indications: r/r multiple myeloma, newly-diagnosed multiple myeloma, r/r B-NHL

100% MRD-

Achieved in all treated r/r and newly-diagnosed multiple myeloma patients

Well capitalized with cash runway for next 24 months

4

Leadership Team

Experienced in R&D and Clinical Development

William Cao, Ph.D., B.M.

Founder, Chairman & CEO

• 30+ years in biotech leadership and R&D
• Co-founderand CEO of Cellular Biomedicine Group
• 100+ issued patents & applications for advanced cell therapies

Wendy Li, M.D.

Chief Medical Officer

• 20+ years of leading all critical aspects of clinical development and medical affairs
• 30+ successful IND, NDA and BLA filings
• CMO of EXUMA Biotech

	Kevin Xie, Ph.D., M.B.A.		Samuel Zhang, Ph.D.		Jenny Ni, M.D., Ph.D.
	Chief Financial Officer		Chief Business Officer	Chief Technology Officer
•	20+ years in healthcare	•	20+ years in BD,	•	25+ years in gene & cell
	investment and corporate		corporate strategy,		therapy, vaccine and
	leadership		and pharmaceutical		contract manufacturing
•	President of Fosun		commercialization	•	Led CMC development
	Healthcare Holdings	•	Global I-O strategy leader		of five IND filings /
•	Portfolio manager at Locust		at Novartis and BMS		approvals for hematological
	CBO of NeoImmuneTech		and solid malignancies
	Walk Capital, Scopia Capital	•

and Great Point Partners

5